EndoClot Plus

Executive Summary

EndoClot Plus, Inc. (EPI) is a privately held medical device company specializing in a novel hemostatic technology for gastrointestinal bleeding. Its flagship product, EndoClot® Polysaccharide Hemostatic System (PHS), is a proprietary absorbable powder sprayed during endoscopy to achieve rapid hemostasis. The device addresses a critical unmet need in GI bleeding management, offering ease of use and effectiveness in challenging anatomical locations. Founded in 2015 and based in San Jose, California, EPI collaborates with leading endoscopists and biomaterial scientists to refine its technology. The company targets the growing endoscopic hemostasis market, driven by increasing rates of GI bleeding and demand for minimally invasive solutions. As a private entity, EPI's financials are undisclosed, but its product has received regulatory clearances in select regions. The company's future growth depends on expanding indications, geographic approvals, and strategic partnerships to scale adoption. With a focused portfolio and strong clinical backing, EPI is positioned to capture share in the competitive hemostasis landscape.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance for expanded indication (e.g., upper GI bleeding or use in bariatric surgery)70% success
• Q4 2026Strategic partnership with a major endoscopy device manufacturer for global distribution50% success
• Q3 2026Publication of pivotal clinical trial results demonstrating non-inferiority to standard-of-care hemostatic agents80% success